argenex (ARGX) Expected to Announce Earnings on Thursday

argenex (NASDAQ:ARGX) is projected to announce its Q2 2026 resultson Thursday, July 23rd. Analysts expect the company to post earnings of $5.86 per share and revenue of $1.45 billion for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 23, 2026 at 6:00 AM ET.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The firm had revenue of $1.31 billion for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. On average, analysts expect argenex to post $26 EPS for the current fiscal year and $34 EPS for the next fiscal year.

argenex Price Performance

NASDAQ ARGX opened at $862.93 on Thursday. The company has a market cap of $53.67 billion, a P/E ratio of 38.42, a P/E/G ratio of 1.06 and a beta of 0.45. The stock has a 50-day moving average of $857.99 and a two-hundred day moving average of $813.17. argenex has a 1-year low of $558.34 and a 1-year high of $953.58.

Institutional Trading of argenex

Several hedge funds have recently added to or reduced their stakes in ARGX. CI Investments Inc. grew its holdings in argenex by 2.6% during the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock valued at $394,000 after buying an additional 12 shares during the last quarter. Raiffeisen Bank International AG lifted its position in shares of argenex by 12.6% in the fourth quarter. Raiffeisen Bank International AG now owns 134 shares of the company’s stock valued at $112,000 after acquiring an additional 15 shares in the last quarter. Laird Norton Wetherby Wealth Management LLC boosted its stake in shares of argenex by 2.7% during the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,253 shares of the company’s stock valued at $924,000 after acquiring an additional 33 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of argenex by 6.9% during the second quarter. Thrivent Financial for Lutherans now owns 527 shares of the company’s stock valued at $295,000 after acquiring an additional 34 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its position in argenex by 10.8% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 391 shares of the company’s stock worth $328,000 after purchasing an additional 38 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of research reports. Royal Bank Of Canada lifted their price objective on shares of argenex from $890.00 to $945.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Wedbush reissued an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research report on Thursday, June 11th. Weiss Ratings upgraded shares of argenex from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, July 6th. Wells Fargo & Company upped their price objective on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Finally, Guggenheim increased their price objective on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $1,037.61.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.